{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:41:08Z","timestamp":1786635668468,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijp.ijp_117_19","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T06:12:15Z","timestamp":1591078335000},"page":"102","source":"Crossref","is-referenced-by-count":2,"title":["SB365 induces apoptosis and suppresses proliferation of glioblastoma cells"],"prefix":"10.4103","volume":"52","author":[{"given":"In-Suh","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Sun","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JooHan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungHee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeeHyeon","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.285723-1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol"},{"key":"key-10.4103\/0253-7613.285723-2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","author":"Stupp","year":"2005","journal-title":"N Engl Med"},{"key":"key-10.4103\/0253-7613.285723-3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/neuonc\/nou166","article-title":"Beating the odds: Extreme long-term survival with glioblastoma","author":"Bi","year":"2014","journal-title":"Neuro Oncol"},{"key":"key-10.4103\/0253-7613.285723-4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.apsb.2014.03.001","article-title":"Brain tumor-targeted drug delivery strategies","author":"Wei","year":"2014","journal-title":"Acta Pharm Sin B"},{"key":"key-10.4103\/0253-7613.285723-5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","article-title":"Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1\u03b1-ZEB1 axis","author":"Joseph","year":"2015","journal-title":"Cancer Lett"},{"key":"key-10.4103\/0253-7613.285723-6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","author":"Rong","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.4103\/0253-7613.285723-7","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.285723-8","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.3390\/ijms15058335","article-title":"Apoptotic death of cancer stem cells for cancer therapy","author":"He","year":"2014","journal-title":"Int J Mol Sci"},{"key":"key-10.4103\/0253-7613.285723-9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1248\/cpb.53.1451","article-title":"Antitumor activity of Pulsatilla koreana saponins and their structure-activity relationship","author":"Bang","year":"2005","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"key-10.4103\/0253-7613.285723-10","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/carcin\/bgt159","article-title":"SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities","author":"Hong","year":"2013","journal-title":"Carcinogenesis"},{"key":"key-10.4103\/0253-7613.285723-11","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.285723-12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canlet.2015.02.005","article-title":"VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGF\u03b2R signaling-dependent manner","author":"Pham","year":"2015","journal-title":"Cancer Lett"},{"key":"key-10.4103\/0253-7613.285723-13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0253-7613.285723-14","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A Multicenter, Phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0253-7613.285723-15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/neuonc\/nos322","article-title":"NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme","author":"Peereboom","year":"2013","journal-title":"Neuro Oncol"},{"key":"key-10.4103\/0253-7613.285723-16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-010-1470-2","article-title":"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer","author":"Kanai","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"key-10.4103\/0253-7613.285723-17","first-page":"421","article-title":"Herbal medicine as inducers of apoptosis in cancer treatment","author":"Safarzadeh","year":"2014","journal-title":"Adv Pharm Bull"},{"key":"key-10.4103\/0253-7613.285723-18","first-page":"9384","article-title":"Therapeutic applications of curcumin for patients with pancreatic cancer","author":"Kanai","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0253-7613.285723-19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1349-7006.2012.02409.x","article-title":"SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K\/Akt\/mTOR signaling pathway","author":"Hong","year":"2012","journal-title":"Cancer Sci"},{"key":"key-10.4103\/0253-7613.285723-20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3892\/or.2013.2517","article-title":"SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells","author":"Son","year":"2013","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0253-7613.285723-21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.foodchem.2012.07.096","article-title":"SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT\/mTOR signalling pathway","author":"Son","year":"2013","journal-title":"Food Chem"},{"key":"key-10.4103\/0253-7613.285723-22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","author":"Elmore","year":"2007","journal-title":"J Toxicol Pathol"},{"key":"key-10.4103\/0253-7613.285723-23","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1158\/1078-0432.CCR-04-1081","article-title":"Hypoxia is important in the biology and aggression of human glial brain tumors","author":"Evans","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0253-7613.285723-24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1541-7786.MCR-06-0235","article-title":"Inhibiting hypoxia-inducible factor 1 for cancer therapy","author":"Melillo","year":"2006","journal-title":"Mol Cancer Res"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:48:46Z","timestamp":1786632526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_117_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["285723"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_117_19","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}